Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CANSINOBIO Completes 1st Patient Enrollment for DTcP-Hib-MCV4 Combined Vaccine
Recommend 0 Positive 2 Negative 0 |
||||
|
||||
|
The Phase I clinical trial for the adsorbed diphtheria, tetanus and acellular pertussis (components) Haemophilus Influenzae Type b (Conjugate)-Group ACYW135 Meningococcal (Conjugate) combined vaccine (the DTcP-Hib-MCV4 Combined Vaccine) developed by CANSINOBIO (06185.HK) was officially initiated recently and the first trial patient case has been formally enrolled, as announced by CANSINOBIO. The clinical trial is designed to assess the safety and immunogenicity of the vaccine in subjects aged between 2 months to 6 years. AAStocks Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
